Utilization of nuclear matrix proteins for cancer diagnosis

Critical Reviews in Eukaryotic Gene Expression

Volumn 6, Issue 2-3, 1996, Pages 189-214

  Keesee, Susan K ^a   Briggman, Joseph V ^a   Thill, Gregory ^a   Wu, Ying Jye ^a  

^a Matritech Inc   (United States)

Author keywords

bladder cancer; NuMA; prostate cancer; tumor marker

Indexed keywords

MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; PHOSPHOPROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

BLADDER CANCER; BODY FLUID; CANCER DIAGNOSIS; CELL NUCLEUS MATRIX; CELL TRANSFORMATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DNA REPLICATION; DNA TRANSCRIPTION; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MITOSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0029811421     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v6.i2-3.50     Document Type: Review

References (213)

1. Abelev GI (1963): Production of embryonal serum alpha globulin by hepatomas. Review of experimental and clinical data. Cancer Res 28:1344-1350.
2. Altausen AF, Prout GR Jr, Daly JJ (1976): Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116:575-580.
3. American Cancer Society (1995): Cancer Facts and Figures, 10-16.
4. Anderson T, Waldmann TA, Javadpour N, Glatstein E(1979): Testicular germ cell neoplasms: recent advances in diagnosis and therapy. Annu Intern Med 90:373-385.
5. Arends MJ, Wyllie AH (1991): Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32:223-254.
6. Bader BL, Magin TM, Freudenmann M, Stumpp S, Franke WW (1991): Intermediate filaments formed de novo from tail-less cytokeratins in the cytoplasm and in the nucleus. J Cell Biol 115:1293-1307.
7. Bartels PH (1992): Computer-generated diagnosis and image analysis. Cancer 69:1636-1638.
8. Baserga R, Porcu P, Sell C (1993): Oncogenes, growth factors and control of the cell cycle. Cancer Surv 16:201-213.
9. Bates SE, Longo DL (1987): Use of serum tumor markers in cancer diagnosis and management. Semin Oncol 14:102-138.
10. Bence-Jones H (1847): Papers on chemical pathology. Lecture III. Lancet 2:269.
11. Berezney R (1991): The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 47:109-123.
12. Berezney R, Coffey DS (1974): Identification of a nuclear protein matrix. Biochem Biophys Res Commun 60:1410-1417.
13. Berman CG, Clark RA (1992): Diagnostic imaging in cancer. Cancer Diag Treat 19:677-713.
14. Berrios M, Osheroff N, Fisher PA (1985): In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82:4142-4146.
15. Berson SA, Yalow RS (1966): Parathyroid hormone in plasma in adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma. Science 154:907-909.
16. Beswuoda WR, Esser JD, Kansey R (1991): The value of estrogen and progesterone receptor determination in advanced breast cancer: estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 68:867-872.
17. Bidwell JP, Fey EG, van Wijnen AJ, Penman S, Stein JL, Lian JB, Stein GS (1994): Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 54:28-32.
18. Bidwell JP, van Wijnen AJ, Fey EG, Dworetzky S, Penman S, Stein JL, Lian JB, Stein GS (1993): Osteocalcin gene promoter binding factors are tissue-specific nuclear matrix components. Proc Natl Acad Sci USA 90:3162-3166.
19. Bieglmayer C, Szepazi T, Kopp B, Hoffmann G, Petrik W (1991): CA 15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumour Biol 12:139-148.
20. Black MM, Speer FD. (1957): Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102.
21. Blasquez VC, Xu M, Moses SC, Garrard WT (1989): Immunoglobulin K gene expression after stable integration. I. Role of the intronic MAR and enhancer in plasmacytoma cells. J Biol Chem 264:21183-21189.
22. Blencowe BJ, Nickerson JA, Issner R, Penman S, Sharp PA (1994): Association of nuclear matrix antigens with exon-containing splicing complexes. J Cell Biol 127:593-607.
23. Blencowe BJ, Issner R, Kim J, McCaw P, Sharp PA (1995): New proteins related to the Ser-Arg family of splicing factors. RNA 1:852-865.
24. Boring CC, Squires TS, Tsong T (1991): Cancer statistics 1991. CA 1991 41:19-36.
25. Boulikas T (1993): Nature of DNA sequences at the attachment regions of genes to the nuclear matrix. J Cell Biochem 52:14-22.
26. Brandt-Rauf PW (1991): Oncogene proteins as biomarkers in the molecular epidemiology of occupational carcinogenesis: the example of the ras oncogene encoded p21 protein. Int Arch Occup Environ Health 63:1-8.
27. Brandt-Rauf PW, DeVivo I, Marion MJ, Hemminki K (1995): The molecular epidemiology of growth signal transduction proteins. J Occup Environ Med 37:77-83.
28. Briggman JV, Astrofsky K, Merrifield SA, Carpenter P, Carpinito GA, Siroky MB, Krane RJ (1992): Detection of nuclear matrix protein in the urine of patients with transitional cell carcinoma. NCI Conference on Chemoprevention of Premalignant and Early Malignant Lesions of the Bladder. Taos, NM.
29. Briggman JV, Meyer J, Oreper A, Coffey DS, Partin AW (1995): Development of a monoclonal antibody PRO:4-216™ to a nuclear matrix protein specific for human prostate cancer. XXIII Meeting of the International Society for Oncodevelopmental Biology and Medicine, Montreal, Canada, p. 41.
30. Brinkley BR, Scott B, Turner D, Zeng C, He D (1995): Nuclear matrix proteins with bifunctional roles in the nucleus and mitotic apparatus. J Cell Biochem (Suppl.)21B:122. Oral presentation at the 24th Annual Keystone Symposia on Molecular and Cellular Biology, Hilton Head, SC.
31. Brinkley BR, Scott B, Turner D, Zeng C, He D (1995): Nuclear matrix proteins with bifunctional roles in the nucleus and mitotic apparatus. J Cell Biochem (Suppl.)21B:122. Oral presentation at the 24th Annual Keystone Symposia on Molecular and Cellular Biology, Hilton Head, SC.
32. Broder LE, Weintraub BD, Rosen SW, Cohen MH, Tejada F (1977): Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 40:211-216.
33. Callahan R, Salomon DS (1993): Oncogenes, tumor suppressor genes and growth factors in breast cancer: novel targets for diagnosis, prognosis and therapy. Cancer Surv 18:35-56.
34. Carpinito GA, Chodak G, Church P, Hayden C, Messing E, Pasciak R, Reservitz G, Rukstalis D, Sarosdy M, Soloway M (1995): A tumor marker for transitional cell carcinoma with high sensitivity. Oral presentation to the New England American Urology Association Conference, Newport, RI.
35. Catalona WJ, Bigg SW (1990): Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143:538-543.
36. Catalona WJ, Hudson MA, Scardino PT (1994a): Selection of optimal prostate-specific antigen cut-offs for early detection of prostate cancer. J Urol 152:2037-2042.
37. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kovoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC (1994b): Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151:1283-1290.
38. Chang F, Syrjänen S, Syrjänen K (1995): Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022.
39. Ciejek EM, Tsai M-J, O'Malley BW (1983): Actively transcribed genes are associated with the nuclear matrix. Nature 306:607-609.
40. Cleveland DW (1995): NuMA: a protein involved in nuclear structure, spindle assembly, and nuclear reformation. Trends Cell Biol 5:60-64.
41. Compton DA, Cleveland DW (1993): NuMA is required for the proper completion of mitosis. J Cell Biol 120:947-957.
42. Compton DA, Luo C (1995): Mutation of the predicted p34cdc2 phosphorylation sites in NuMA impair the assembly of the mitotic spindle and block mitosis. J Cell Sci 108:621-633.
43. Compton DA, Szilak I, Cleveland DW (1992): Primary structure of NuMA, an intranuclear protein that defines a novel pathway for segregation of proteins at mitosis. J Cell Biol 116:1395-1408.
44. Coon JS, Landay AL, Weinstein RS (1987): Biology of disease: advances in flow cytometry for diagnostic pathology. Lab Invest 57:453-479.
45. Costa J, Wesley RA, Glatstein E, Rosenberg SA (1984): The grading of soft tissue sarcomas. Cancer 53:530-541.
46. Dejgaard K, Leffers H, Rasmussen HH, Madsen P, Kruse TA, Gesser B, Nielsen H, Celis JE (1994): Identification, molecular cloning, expression and chromosome mapping of a family of transformation upregulated hnRNP-K proteins derived by alternative splicing. J Mol Biol 236:33-48.
47. Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffey DS. (1982a): A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol 128:729-734.
48. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS. (1982b): Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 3:321-332.
49. Donehower LA, Bradley A. (1993): The tumor suppressor p53. Biochim Biophys Acta 1155:181-205.
50. Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG (1993): hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 62:289-321.
51. Duvall E, Wyllie AH (1986): Death and the cell. Immunol Today 7:115-119.
52. Dworetsky SI, Wright KL, Fey EG, Penman S, Lian JB, Stein JL, Stein GS (1992): Sequence-specific DNA-binding proteins are components of a nuclear matrix-attachment site. Proc Natl Acad Sci USA 89:4178-4182.
53. Fair WR, Fuks ZY, Scher HI (1993): Cancer of the bladder. In DeVita VT, Hellman S, Rosenberg (eds): "Cancer: Principles and Practice of Oncology," 4th ed, Vol 1, Philadelphia: JB Lippincott and Company, 1056-1069.
54. Feller WF (1991): Mucin glycoproteins as tumour markers. In Herberman RB, Mercer DW (eds): "Immunodiagnosis of Cancer," 2nd ed, New York: Marcel Dekker, 631-672.
55. Fernandez-Patron C, Castellanos-Serra L, Rodriguez P (1992): Reverse staining of sodium dodecyl sulfate polyacrylamide gels by imidazole-zinc salts: sensitive detection of unmodified proteins. Biotechniques 12:564-573.
56. Fey EG, Bangs P, Sparks C, Odgren P (1991): The nuclear matrix: defining structural and functional roles. Crit Rev Eukary Gene Exp 1:127-143.
57. Fey EG, Krochmalnic G, Penman S (1986a): The nonchromatin substructures of the nucleus: the ribonucleoprotein (RNP)-containing and RNP-depleted matrices analyzed by sequential fractionation and resinless section electron microscopy. J Cell Biol 102:1654-1665.
58. Fey EG, Penman S (1986b): Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci USA 85:121-125.
59. Fey EG, Wan KM, Penman S (1984): Epithelial cytoskeletal framework and nuclear matrix-intermediate filament scaffold: three-dimensional organization and protein composition. J Cell Biol 98:1973-1984.
60. Field JK, Spandidos DA (1990): The role of ras and myc oncogenes in human and solid tumours and their relevance in diagnosis and prognosis. Anticancer Res 10:1-22.
61. Fisher C (1990): The value of electron microscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology 16:441-454.
62. Fisher DZ, Chaudhary N, Blobel G (1986): cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci USA 83:6450-6454.
63. Flens MJ, van der Valk P, Tadema TM, Huysmans AC, Risse EK, van Tol GA, Meijer CJ (1990): The contribution of immunocytochemistry in diagnostic cytology: comparison and evaluation with immunohistology. Cancer 65:2704-2711.
64. Gallee MPW, Ten Kate FJW, Mulder GH (1990): Histological grading of prostate carcinoma in prostatectomy specimens: a comparison of prognostic accuracy of five grading systems. Br J Urol 65:368-375.
65. Gerace L, Blobel G (1982): Nuclear lamina and the structural organization of the nuclear envelope. Cold Spring Harb Symp Quant Biol 46:967-978.
66. Gerace L, Blum A, Blobel G (1987): Immunocytochemical localization of the major polypeptides of the nuclear pore complex-lamina fraction. J Cell Biol 79:546-566.
67. Gerace L, Comeau C, Benson M (1984): Organization and modulation of the nuclear lamina structure. J Cell Sci (Suppl.) 1:137-160.
68. Getzenberg RH, Pienta KJ, Coffey DS. (1990): The tissue matrix: cell dynamics and hormone action. Endocrinol Rev 11:399-417.
69. Getzenberg RH, Pienta KJ, Huang EY, Coffey DS (1991): Identification of nuclear matrix proteins in the cancer and normal prostate. Cancer Res 51:6514-6520.
70. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakarm A, Becich MJ, Bahnson BR (1996): Bladder cancer associated nuclear matrix proteins. Cancer Res 56:1690-1694.
71. Gleason DF (1992): Histologic grading of prostate cancer: a perspective. Hum Pathol 23:273-280.
72. Gold P, Freedman SO (1965): Demonstration of tumor specific antigens in human colonic carcinoma by immunologic tolerance and absorption techniques. J Exp Med 121:439-462.
73. Goodrich DW, Lee W (1993): Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1155:43-61.
74. Gutman AB, Gutman EB (1938): An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 17:473-478.
75. Handley MR, Stuart ME (1994): The use of prostate-specific antigen for prostate cancer screening: a managed care perspective. J Urol 152:1689-1692.
76. Harrington EA, Fanidi A, Evan GI (1994): Oncogenes and cell death. Curr Opin Genet Dev 4:120-129.
77. He D, Nickerson JA, Penman S (1990): Core filaments of the nuclear matrix. J Cell Biol 110:569-580.
78. Henson DE, Ries L, Freedman LS, Carriaga M (1991): Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: the basis for a prognostic index. Cancer 68:2142-2149.
79. Herr HW, Ludone VP (1989): "Intravesical therapy for superficial bladder cancer. AUA Update Series," Vol 8, Lesson 12, Bellaire, Texas: American Urological Associates Office of Education.
80. Hoppe-Seyler F, Butz K (1994): Tumor suppressor genes in molecular medicine. Clin Invest 72:619-630.
81. Hunter T, Pines J (1994): Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
82. Innes DJ, Feldman PS (1983): Comparison of diagnostic results obtained by fine needle aspiration cytology and Tru-Cut or open biopsies. Acta Cytol 27:350-354.
83. Jacobs I, Bast R (1989): The CA 125 tumour associated antigen: a review of the literature. Hum Reprod 4:1-12.
84. Kallajoki M, Osborn M (1994): Gel electrophoretic analysis of nuclear matrix fractions isolated from different human cell lines. Electrophoresis 15:520-528.
85. Kallajoki M, Harborth J, Weber K, Osborn M (1993): Micro-injection of a monoclonal antibody against SPN antigen, now identified by peptide sequences as the NuMA protein, induces micronuclei in PtK2 cells. J Cell Sci 102:91-102.
86. Kallajoki M, Weber K, Osborn M (1991): A 210 kD nuclear matrix protein is a functional part of the mitotic spindle: a microinjection study using SPN monoclonal antibodies. EMBO J 7:3667-3678.
87. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr (1988): Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 48:3853-3855.
88. Kaufman SH, Shaper JH (1984): A subset of non-histone nuclear proteins reversibly stabilized by the sulfhydryl cross-linking reagent tetrathionate: polypeptides of the internal nuclear matrix. Exp Cell Res 155:477-495.
89. Keesee, SK, Meneghini MD, Szaro RP, Wu YJ (1994): Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 91:1913-1916.
90. Kerr JFR, Lamb D (1984): Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 50:343-349.
91. Kerr JFR, Searle (1972): Suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 107:41-44.
92. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ (1993): Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53:3394-3398.
93. Khoo SK, Hurst T, Webb MJ, Dickie GJ, Kearsley JH, Mackay EV (1987): Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomy. Eur J Cancer Clin Oncol 23:765-772.
94. Klehr D, Schlake T, Maass K, Bode J (1991): Scaffold-attached regions from the human Interferon β domain can be used to enhance the stable expression of genes under the control of various promoters. Biochemistry 30:1264-1270.
95. Kohler H, Milstein C (1975): Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature 256:495-497.
96. Koss LG (1975): "Atlas of Tumor Pathology: Tumors of the Urinary Bladder (Fasicle 11)," 2nd ed, Washington, D.C.: Armed Forces Institute of Pathology.
97. Koss LG (1979a): The urinary tract in the absence of cancer. In Koss LG (ed): "Diagnostic Cytology and its Histopathologic Bases," 3rd ed, Vol 2. Philadelphia: JB Lippincott and Company, 724-725.
98. Koss LG (1979b): Tumors of the urinary tract and prostate. In Koss LG (ed): "Diagnostic Cytology and its Histopathologic Bases," 3rd ed, Vol 2. Philadelphia: JB Lippincott and Company, 761.
99. Kraus M, Wolf B (1993): Emergence of self-organization in tumor cells: relevance for diagnosis and therapy. Tumour Biol 14:338-353.
100. Krebs HB, Goplerud DR, Kilpatrick SJ, Myers MB, Hunt A (1986): Role of CA 125 as tumor marker in ovarian carcinoma. Obstet Gynecol 67:473-477.
101. Krohne G, Wolin SL, McKeon FD, Franke WW, Kirschner MW (1987): Nuclear lamin L1 of Xenopus laevis: cDNA cloning, amino acid sequence and binding specificity of a member of the lamin B subfamily. EMBO J 6:3801-3808.
102. Krontiris TG (1995): Oncogenes. N Engl J Med 333:303-306.
103. Kühn S, Vorgias CE, Traub P (1987): Interaction in vitro of non-epithelial intermediate filament proteins with supercoiled plasmid DNA. J Cell Sci 87:543-554.
104. Kuriyama M, Wang MC, Lee C-I, Papsidero LD, Kilian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM (1981): Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41:3874-3876.
105. Kyprianou N, English HF, Isaacs JT (1990): Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753.
106. Lala PK (1972): Evaluation of the mode of cell death in Ehrlich ascites tumor. Cancer 29:261-266.
107. Laster SM, Wood JG, Gooding LR (1988): Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 141:2629-2634.
108. Lawrence JB, Singer RH, Marselle LM (1989): Highly localized tracks of specific transcripts within interphase nuclei visualized by in situ hybridization. Cell 57:493-502.
109. Lebel S, Raymond Y (1987): Lamins A, B and C share an epitope with the common domain of intermediate filament proteins. Exp Cell Res 169:560-565.
110. Levine AJ, Momand J, Finlay CA (1991): The p53 tumor suppressor gene. Nature 351: 453-456.
111. Lieber MM (1992): DNA content/ploidy as prognostic factors in prostate cancer. Prostate 4:119-124.
112. Lydersen BK, Pettijohn DE (1980): Human-specific nuclear protein that associates with the polar region of the mitotic apparatus: distribution in a human/hamster hybrid cell. Cell 22:489-499.
113. Maekawa T, Leslie R, Kuriyama R (1991): Identification of a minus end-specific microtubule-associated protein located at the mitotic poles in cultured mammalian cells. Eur J Cell Biol 54:255-267.
114. Magdelenat H (1992): Tumour markers in oncology: past, present and future. J Immunol Methods 150:133-143.
115. Marangos PJ (1985): Clinical studies with neuron specific enolase. Prog Clin Biol Res 175:285-294.
116. McKeon FD, Kirschner MW, Caput D (1986): Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature 319:463-467.
117. Merrifield SA, Roos R, Shapiro K, Borden K, Briggman JV (1996): An immunoassay that quantifies the level of a nuclear matrix protein in the urine of patients with bladder cancer. (Submitted).
118. Miller TE, Beausang LA, Meneghini M, Lidgard G (1993a): Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis. Biotechniques 15:1042-1047.
119. Miller TE, Beausang LA, Meneghini M, Lidgard GP (1993b): Cell death and nuclear matrix proteins. In Tomei LD, Cope FO (eds): "Current Communications in Cell and Molecular Biology, Vol 8. Apoptosis, II: The Molecular Basis of Apoptosis in Disease." Plainview, NY: Cold Spring Harbor Laboratory Press, 357-376.
120. Miller TE, Beausang LA, Winchell LF, Lidgard GP (1992): Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 52:422-427.
121. Mirkovitch J, Mirault ME, Laemmli UK (1984): Organization of the higher order chromatin loop: specific DNA attachment sites on nuclear scaffold. Cell 39:223-232.
122. Moertel CG, Fleming TR, Macdonald JS, Lailer DG, Laurie JA, Tangen C (1993): An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. J Am Med Assoc 270:943-947.
123. Morrison WB, DeNicola DB (1993): Advantages and disadvantages of cytology and histopathology for the diagnosis of cancer. Semin Vet Med Surg (Small Anim) 8:222-227.
124. Mostofi FC, Sobin LH, Torloni H (1973): Histologic typing of urinary bladder tumours. In, "International Histological Classification of Tumors," Vol 10, Geneva: WHO Monogr Ser.
125. Mulder JR, Offerhaus JA, de Feyter EP, Floyd JJ, Kern SE, Vogelstein B, Hamilton SR (1992): The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am J Pathol 141:797-804.
126. Murphy WM (1990): Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 21:886-896.
127. Murphy WM (1993): Urine cytology: what we can and can't do. Cyto Teleconference. Philadelphia: American Society of Cytology, 3.
128. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL (1990): The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619-1625.
129. Nelson WG, Coffey DS (1987): Structural aspects of mammalian DNA replication: topoisomerase II. Natl Cancer Inst Monogr 4:23-29.
130. Nickerson JA, He D, Fey EG, Penman S (1990): The nuclear matrix. In Strauss PR, Wilson SH (eds): "The Eukaryotic Nucleus: Molecular Biochemistry and Macromolecular Assemblies," Vol 2, Caldwell, NJ: Telford Press.
131. Nickerson JA, Krockmalnic G, Wan KM, Turner CD, Penman S (1992): A normally masked nuclear matrix antigen that appears at mitosis on cytoskeleton filaments adjoining chromosomes, centrioles, and midbodies. J Cell Biol 116:977-987.
132. Nielsen K, Orntoft T, Wolf H (1989): Stereologic estimates of nuclear volume in noninvasive bladder tumors (Ta) correlated with the recurrence pattern. Cancer 64:2269-2274.
133. Obar RA, Briggman J, Keesee SK, Marchese J, Foehl DH, Szaro RP, Wu Y-J, Subong ENP, Partin AW (1996): Characterization of PC-1, a nuclear matrix component correlated with prostate cancer. To be presented at the 1996 American Urological Association Meeting, Orlando, FL.
134. Ogata N (1990): Preferential association of a transcriptionally active gene with the nuclear matrix of rat fibroblasts by a simian virus 40-pBR322 recombinant plasmid. Biochem J 267:385-390.
135. Orntoft TF, Bech E (1995): Circulating blood group related carbohydrate antigens as tumour markers. Glycoconj J 12:200-205.
136. Osborn M, Weber K (1987): Cytoplasmic intermediate filament proteins and the nuclear lamins A, B and C share the IFA epitope. Exp Cell Res 170:195-203.
137. Pandha HS, Waxman J (1995): Tumour markers. Q J Med 88:233-241.
138. Paredes JM, Mitchell BS (1980): Multiple myeloma. Current concepts in diagnosis and management. Med Clin N Am 64:729-742.
139. Partin AW, Oesterling JE (1994): The clinical usefulness of prostate specific antigen: update 1994. J Urol 152:1358-1368.
140. Partin AW, Briggman JV, Oreper A, Meyer J, Wiesbrock S, Vindivich D, Coffey D, Epstein J (1996): Immunohistochemical detection of prostate cancer using the antinuclear matrix protein PRO 4:216 antibody. (Manuscript in preparation).
141. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS (1993): Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53:744-746.
142. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI (1992a): Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease-free survival among patients with prostate cancer. Cancer 70:161-168.
143. Partin AW, Lee BR, Chan DW, Epstein JI, Walsh PC (1992b): The use of prostate specific antigen PSA and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol (Suppl)147(4):387A.
144. Perucho M (1994): PCR and cancer diagnostics: detection and characterization of single point mutations in oncogenes and antioncogenes. In Mullis KB, Ferre Fand Gibbs RA (eds): "The Polymerase Chain Reaction". Boston: Birkhauser.
145. Pettinato G, Manivel JC, Petrella G, Jassim AD (1991): Fine needle aspiration cytology, immunocytochemistry and electron microscopy: fibromatosis of the breast. Acta Cytol 35:403-408.
146. Phi-Van L, von Kries JP, Ostertag W, Strätling WH (1990): The chicken lysozyme 5′ matrix attachment region increases transcription from a heterologous promoter in heterologous cells and dampens position effects on the expression of transfected genes. Mol Cell Biol 10:2302-2307.
147. Pienta KJ, Coffey DS (1989): Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 49:2525-2532.
148. Pienta KJ, Coffey DS (1991b): Correlation of nuclear morphometry with progression of breast cancer. Cancer 68:2012-2016.
149. Pienta KJ, Getzenberg RH, Coffey DS (1991a): Cell structure and DNA organization. Crit Rev Eukary Gene Exp 1:355-383.
150. Preisler HD, Raza A (1992): The role of emerging technologies in the diagnosis and staging of neoplastic diseases. Cancer 69:1520-1526.
151. Prout GR Jr (1977): Bladder carcinoma and a TNM system of classification. J Urol 117:583-590.
152. Ramsey-Ewing A, van Wijnen AJ, Stein GS, Stein JL (1994): Delineation of a human histone H4 cell cycle element in vivo: the master switch for H4 gene transcription. Proc Natl Acad Sci USA 91:4475-4479.
153. Rapellino M, Pecchio F, Baldi S, Scappaticci E, Cavallo A (1995): Clinical utility of tissue polypeptide antigen determination in lung cancer management. Anticancer Res 15:1065-1070.
154. Razin SV, Vassetzky YS, Hancock R (1991): Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin. Biochem Biophys Res Commun 177:265-270.
155. Rodriguez-Tarduchy G, Collins M, Lopez-Rives A (1990): Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J 9:2997-3002.
156. Rosai J (1993): Principles of oncologic pathology. In DeVita VT, Hellman S, Rosenberg SA (eds): "Cancer. Principles and Practice", 4th ed, Vol 1, Philadelphia: JB Lippincott and Company, 228-230.
157. Roussel F, Nouvel G (1995): Evaluation of large needle biopsy for the diagnosis of cancer. Acta Cytol 39:449-452.
158. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995): Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
159. Sarosdy MF, DeVereWhite RW, Soloway MS, Sheinfeld J, Hudson MS, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA (1995): Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154:379-384
160. Sarraf CE, Bowen ID (1988): Proportions of mitotic and apoptotic cells in a range of untreated experimental tumors. Cell Tissue Kinet 21:45-49.
161. Schwartz MK (1987): Biochemical and immunological diagnosis of cancer. Germ cell tumors. Tumour Biol 8:106-108.
162. Schwartz MK (1993): Specialized techniques of cancer management and diagnosis: Section 3. Cancer Markers. In DeVita VT, Hellman S, Rosenberg SA (eds): "Cancer Principles and Practice", 4th ed, Vol 1, Philadelphia: JB Lippincott and Company, 228-230.
163. Schwartz MK (1995a): Current status of tumour markers. Scand J Clin Lab Invest 55(Suppl)221:5-14.
164. Schwartz MK (1995b): Tissue cathepsins as tumor markers. Clin Chim Acta 237:67-78.
165. Sershon PD, Barry MJ, Oesterling JE (1994): Serum prostate specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ confined prostate cancer. Eur Urol 25:281-287.
166. Shenoy UA, Colby TX, Schumann GB (1985): Reliability of urinary cytodiagnosis in urothelial neoplasms. Cancer 56:2041-2045.
167. Silverberg E, Boring CC, Squires TS (1990): Cancer statistics 1990. Ca 1990 40:1.
168. Slamon DJ, Godolphin W (1989): Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712.
169. Small D, Nelkin B, Vogelstein B (1985): The association of transcribed genes with the nuclear matrix of drosophila cells during heat shock. Nucleic Acids Res 13:2413-2431.
170. Soletermos G, Nielsen D, Schioler V, Skovsgaard T, Windel P, Mouridsen HT, Dombernowsky P (1993): A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Annu Oncol 4:861-869.
171. Sorensen FB, Bichel P, Jakobsen A (1992): DNA level and stereologic estimates of nuclear volume in squamous cell carcinomas of the uterine cervix. Cancer 69:187-199.
172. Sorensen FB, Kristensen IB, Grymer F, Jakobsen A (1991): DNA-level, tumor thickness, and stereological estimates of nuclear volume in stage I cutaneous malignant melanomas. A comparative study with analysis of prognostic impact. Am J Dermatopathol 13:11-19.
173. Sparks CA, Bangs PL, McNeil GP, Lawrence JB, Fey EG (1993): Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13. Genomics 17:222-224.
174. Stanbridge EJ (1992): Functional evidence for human tumor suppressor genes: chromosome and molecular genetic studies. Cancer Surv 12:5-24.
175. Stein GS, Lian JB (1995a): Molecular mechanisms mediating proliferation-differentiation interrelationships during progressive development of the osteoblast phenotype: update 1995. Endocrinol Rev 4:290-297.
176. Stein GS, Stein JL, van Wijnen AJ, Lian JB (1996): The maturation of a cell. Am Sci 84:28-37.
177. Stein GS, Stein JL, van Wijnen AJ, Lian JB, Quesenberry PJ (1995b): Molecular mechanisms mediating cell cycle and cell growth control. Exp Hematol 23:1053-1061.
178. Steinert PM, Roop DR (1988): Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 57:593-625.
179. Stuurman N, Meijne AML, van der Pol AJ, de Jong L, van Driel R, van Renswoude J (1990): The nuclear matrix from cells of different origin. Evidence for a common set of matrix proteins. J Biol Chem 265:5460-5465.
180. Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L, van Driel R (1992): A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 101:773-784.
181. Szende B, Zalatini A, Serially AV (1989): Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86:1643-1647.
182. Tang TK, Tang CC, Chen Y, Wu C (1993): Nuclear proteins of the bovine esophageal epithelium II: the NuMA gene gives rise to multiple mRNAs and gene products reactive with monoclonal antibody W1. J Cell Sci 104:249-260.
183. Theissig P, Zimmer V, Haroske G, Kunze KD, Meyer W (1991): Use of nuclear image cytometry, histopathological grading and DNA cytometry to make breast cancer prognosis more objective. Anal Cell Pathol 3:351-355.
184. Thibodeau A, Vincent M (1991): Monoclonal antibody CC-3 recognizes phosphoproteins in interphase and mitotic cells. Exp Cell Res 195:145-153.
185. Thomas CMG, Segers MFG, Houx PEW (1985): Comparison of the analytical characteristics and clinical usefulness in tumor monitoring of fifteen hCG (beta) immunoassay kits. Annu Clin Biochem 22:236-246.
186. Todorov IT, Philidova RN, Joswig G, Werner D, Ramaekers FCS (1992): Detection of the 125 kDa nuclear protein mitotin in centrosomes, the poles of the mitotic spindle, and the midbody. Exp Cell Res 199:398-401.
187. Tousson A, Zeng C, Brinkley BR, Valdivia MM (1991): Centrophilin: a novel mitotic spindle protein involved in microtubule nucleation. J Cell Biol 112:427-440.
188. Traub P, Shoeman RL (1994): Intermediate filament proteins: cytoskeletal elements with gene-regulatory function? Int Rev Cytol 154:1-103.
189. Traub P, Perides G, Kühn S, Scherbarth A (1986): Interaction in vitro of non-epithelial intermediate filament proteins with histones. Z Naturforsch (C) 42C:47-63.
190. Traub P, Mothes E, Shoeman RL, Kühn S, Scherbarth A (1992): Characterization of the nucleic acid-binding activities of the isolated amino-terminal head domain of the intermediate filament protein vimentin reveals its close relationship to the DNA-binding regions of some prokaryotic single-stranded DNA-binding proteins. J Mol Biol 228:41-57.
191. Trump BF, Berezesky IK, Osornio-Vargas AR (1981): Cell death and the disease process. The role of calcium. In Bowen ID, Lockshin RA (eds): "Cell Death in Biology and Pathology". London/New York: Chapman and Hall, 209-242.
192. Van der Schouw YT, Segers MFG, Smits L, Thomas CMG, Verbeek ALM, Wobbes T (1993): Towards a more standardized assessment of diagnostic tumour markers. Int J Oncol 3:979-985.
193. van Wijnen AJ, Bidwell JP, Fey EG, Penman S, Lian JB, Stein JL, Stein GS (1993): Nuclear matrix association of multiple sequence-specific DNA binding activities related to SP-1, ATF, CCAAT, C/EBP, OCT-1 and AP-1. Biochemistry 32:8397-8402.
194. von Kries J, Buhrmester H, Strätling WH (1991): A matrix/ scaffold attachment region binding protein: identification, purification and mode of binding. Cell 65:123-135.
195. Waldmann TA (1991): Monoclonal antibodies in diagnosis and therapy. Science 252:1657-1662.
196. Wan JM, Nickerson JA, Krochmalnic G, Penman S (1994): The B1C8 protein is in the dense assemblies of the nuclear matrix and relocates to the spindle and pericentriolar filaments at mitosis. Proc Natl Acad Sci USA 91:594-598.
197. Wasserstrom WK, Schwartz MK, Fleisher M, Posner JB (1981): Cerebrospinal fluid biochemical markers in central nervous system tumors: a review. Annu Clin Lab Sci 11:239-251.
198. Wells SA Jr, Baylin SB, Gann DS, Farrell RE, Dilley WG, Preissig SH, Linehan WM, Cooper CW (1978): Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Annu Surg 188:377-383.
199. Wepsic HT (1981): Alpha-fetoprotein: its quantitation and relationship to neoplastic disease. In Kirkpatrick AM, Nakamura RM (eds): "Alphafetoprotein. Laboratory Procedures and Clinical Applications". New York: Masson, 115-129.
200. Whitfield WGF, Millar SE, Saumweber H, Frasch M, Glover DM (1988): Cloning of a gene encoding an antigen associated with the centrosome in Drosophila. J Cell Sci 89:467-480.
201. Whitmore WF Jr (1986): Bladder cancer: future directions in management. Proceedings of a symposium at Marco Island, FL: John Wiley and Sons Medical Group.
202. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JI, Clarkepearson DL, Oran DH, Bast RC (1993): Elevation of multiple serum markers in patients with stage-I ovarian cancer. J Natl Cancer Inst 85:1748-1752.
203. Wyllie AH (1985): The biology of cell death in tumours. Anticancer Res 5:131-136.
204. Wyllie AH, Kerr JF, Currie AR (1980): Cell death: the significance of apoptosis. Int Rev Cytol 68:251-306.
205. Wyllie AH, Morris RG, Smith AL, Dunlop D (1984): Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142:67-78.
206. Xing Y, Johnson CV, Dobner PR, Lawrence JB (1993): Higher level organization of individual gene transcription and RNA splicing. Science 259:1326-1330.
207. Yang CH, Snyder M (1992): The nuclear-mitotic apparatus protein (NuMA) is important in the establishment and maintenance of the bipolar mitotic spindle apparatus. Mol Biol Cell 3:1259-1267.
208. Yang CH, Lambie EJ, Synder M (1992): NuMA: an unusually long coiled coil related protein in the mammalian nucleus. J Cell Biol 116:1303-1317.
209. Yedema CA, Kenemans P, Tomas CM, Massuger LF, Wobbes T, Verstraeten R, Vankamp GJ, Hilgers J (1993): CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 29A:966-971.
210. Zein T, Wajsman Z, Englander LS, Gamarra M, Lopez C, Huben RP, Pontes JE (1984): Evaluation of bladder washings and urine cytology. I. The diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa. J Urol 132:670-671.
211. Zeng C, He D, Brinkley BR (1994a): Localization of NuMA protein isoforms in the nuclear matrix of mammalian cells. Cell Motil Cytoskeleton 29:167-176.
212. Zeng C, He D, Berget SM, Brinkley BR (1994b): Nuclearmitotic apparatus protein: a structural interface between the nucleoskeleton and RNA splicing. Proc Natl Acad Sci USA 91:1505-1509.
213. Zusman I (1994): Variability of serum tumor-associated antigens and their significance in cancer diagnosis (Review). Oncol Rep 1:997-1009.